Abstract
Obesity is considered a worldwide epidemic. Weight reduction by means of lifestyle changes is difficult to achieve, and pharmacotherapy is frequently needed. Although all currently approved anti-obesity agents have proven to be effective to achieve some degree of weight reduction and improve cardiometabolic risk factors, different compounds differ in their mechanism of action and safety profile. However, it is still difficult to achieve and maintain therapeutic objectives along time. The aim of the present article is to summarize the main characteristics of available anti-obesity agents and to explore novel agents that may provide significant clinical benefits in the future.
Keywords: Anti-obesity agents, obesity, pharmacotherapy, sibutramine, orlistat, rimonabant
Current Clinical Pharmacology
Title: Recent Advances in Obesity Pharmacotherapy
Volume: 4 Issue: 1
Author(s): Marcos A. Mayer, Christian Hocht, Ana Puyo and Carlos A. Taira
Affiliation:
Keywords: Anti-obesity agents, obesity, pharmacotherapy, sibutramine, orlistat, rimonabant
Abstract: Obesity is considered a worldwide epidemic. Weight reduction by means of lifestyle changes is difficult to achieve, and pharmacotherapy is frequently needed. Although all currently approved anti-obesity agents have proven to be effective to achieve some degree of weight reduction and improve cardiometabolic risk factors, different compounds differ in their mechanism of action and safety profile. However, it is still difficult to achieve and maintain therapeutic objectives along time. The aim of the present article is to summarize the main characteristics of available anti-obesity agents and to explore novel agents that may provide significant clinical benefits in the future.
Export Options
About this article
Cite this article as:
Mayer A. Marcos, Hocht Christian, Puyo Ana and Taira A. Carlos, Recent Advances in Obesity Pharmacotherapy, Current Clinical Pharmacology 2009; 4 (1) . https://dx.doi.org/10.2174/157488409787236128
DOI https://dx.doi.org/10.2174/157488409787236128 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
Related Articles
-
Current Pathogenesis of Alzheimer’s Disease and Plants Derived Neuroprotective Phytoconstituents: A Comprehensive Review
Current Psychopharmacology Post-Translational Protein Modifications of Rare and Unconventional Types: Implications in Functions and Diseases
Current Medicinal Chemistry Environmental Enrichment as a Positive Behavioral Intervention Across the Lifespan
Current Neuropharmacology Ribonucleases and ImmunoRNases as Anticancer Drugs
Current Pharmaceutical Design Insights Into Effects of Ellagic Acid on the Nervous System: A Mini Review
Current Pharmaceutical Design Chemistry and Biochemistry of Oxidative Stress in Neurodegenerative Disease
Current Medicinal Chemistry A Multicenter, Double-Blind, Placebo-Controlled Trial of the PDE9A Inhibitor, PF-04447943, in Alzheimer's Disease
Current Alzheimer Research AMPK Function in Aging Process
Current Drug Targets Ryanodine Receptor Patents
Recent Patents on Biotechnology Immunophilin Dysfunction and Neuropathology
Current Medicinal Chemistry Re-Wiring the Circuit: Mitochondria as a Pharmacological Target in Liver Disease
Current Medicinal Chemistry Biosynthesis of Flavin Cofactors in Man: Implications in Health and Disease
Current Pharmaceutical Design Editorial (Thematic Issue: Induced Cell-Based Transplantation to Therapeutically Target Spinal Cord Disorders)
Current Stem Cell Research & Therapy Biochemical and Therapeutic Effects of Antioxidants in the Treatment of Alzheimers Disease, Parkinsons Disease, and Amyotrophic Lateral Sclerosis
Current Drug Targets - CNS & Neurological Disorders Oxidative Stress, Antioxidants and Neurodegenerative Diseases
Current Pharmaceutical Design Current Concepts on Selected Plant Secondary Metabolites With Promising Inhibitory Effects Against Enzymes Linked to Alzheimer’s Disease
Current Medicinal Chemistry Prospective Role of Polyphenolic Compounds in the Treatment of Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Cytokine-Induced Depression: Current Status and Novel Targets for Depression Therapy
CNS & Neurological Disorders - Drug Targets Molecular Links Between Endothelial Dysfunction and Neurodegeneration in Alzheimer's Disease
Current Alzheimer Research Primary Progressive Aphasia-Defining Genetic and Pathological Subtypes
Current Alzheimer Research